Study wrapper · #745
MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment.
Editor's note
This review centres squarely on MOTS-c in type 2 diabetes, from risk factors through cardiac complications, and usefully compiles the exogenous MOTS-c dosing approaches used across preclinical metabolic studies, a practical reference for the field. Its thesis is that insufficient MOTS-c from dysfunctional mitochondria contributes to diabetes and its complications via retrograde signalling. As a review it synthesises mechanism and association rather than demonstrating outcomes, and the therapeutic evidence it draws on is preclinical. No human efficacy data are presented, and the dosing summaries describe animal protocols, not clinical guidance. Publishable as directly relevant landscape context with clear framing that MOTS-c in diabetes remains a preclinical, mechanism-and-biomarker story awaiting human trials.
Plain-language abstract
This review focuses on MOTS-c, a mitochondria-derived peptide, in type 2 diabetes. It explains how too little MOTS-c, coming from poorly functioning mitochondria, may contribute to the development of diabetes and its complications, especially heart problems like diabetic cardiomyopathy. The authors gather how MOTS-c relates to various diabetes risk factors and organise the findings in tables. A particularly practical part compiles the different doses and dosing schedules that researchers have used when giving MOTS-c in animal studies of metabolic disease, which is useful for planning future research. Because it is a review of existing laboratory and animal work rather than a human trial, it does not show that MOTS-c helps people with diabetes, and the dosing information describes animal experiments, not medical advice. For readers, it offers a well-organised overview of the MOTS-c-diabetes connection and makes clear this remains early-stage science needing human studies.